Abstract
Objective: Glucagon-like peptide-1 (GLP-1) receptor agonists are available for the treatment of type 2 diabetes. We assessed the efficacy of exenatide and liraglutide to reach the HbA1c target of 2 value=0.513, p
Original language | English |
---|---|
Pages (from-to) | 1519-1528 |
Number of pages | 10 |
Journal | Current Medical Research and Opinion |
Volume | 27 |
Issue number | 8 |
DOIs | |
Publication status | Published - Aug 2011 |
Keywords
- Clinical trials
- Exenatide
- GLP-1 analogues
- HbA1c <7%
- Liraglutide
- Type 2 diabetes
ASJC Scopus subject areas
- Medicine(all)